Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 7.4% in January

Krystal Biotech, Inc. (NASDAQ:KRYS) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 3,010,000 shares, a drop of 7.4% from the January 15th total of 3,250,000 shares. Based on an average daily volume of 262,600 shares, the short-interest ratio is presently 11.5 days.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Citigroup boosted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Chardan Capital reiterated a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a report on Wednesday, December 18th. Finally, HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Krystal Biotech has an average rating of “Buy” and an average target price of $206.67.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded down $2.51 on Monday, hitting $153.24. 129,478 shares of the company’s stock were exchanged, compared to its average volume of 236,087. The firm’s 50-day moving average is $158.61 and its 200 day moving average is $175.74. The company has a market capitalization of $4.41 billion, a PE ratio of 86.58 and a beta of 0.84. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Summit Trail Advisors LLC acquired a new position in shares of Krystal Biotech during the 3rd quarter worth about $1,893,000. Swiss National Bank lifted its holdings in shares of Krystal Biotech by 8.0% in the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after purchasing an additional 2,900 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of Krystal Biotech in the 4th quarter valued at about $548,000. Janney Montgomery Scott LLC lifted its holdings in shares of Krystal Biotech by 42.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after purchasing an additional 15,545 shares during the last quarter. Finally, Citigroup Inc. lifted its holdings in shares of Krystal Biotech by 65.4% in the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after purchasing an additional 13,874 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).